CORONA Remedies Limited (NSE:CORONA)

CORONA Remedies Statistics

Total Valuation

CORONA Remedies has a market cap or net worth of INR 102.46 billion. The enterprise value is 103.66 billion.

Market Cap	102.46B
Enterprise Value	103.66B

Important Dates

The last earnings date was Monday, May 11, 2026.

Earnings Date	May 11, 2026
Ex-Dividend Date	n/a

Share Statistics

CORONA Remedies has 61.16 million shares outstanding. The number of shares has decreased by -0.01% in one year.

Current Share Class	61.16M
Shares Outstanding	61.16M
Shares Change (YoY)	-0.01%
Shares Change (QoQ)	+0.05%
Owned by Insiders (%)	69.00%
Owned by Institutions (%)	5.55%
Float	6.17M

Valuation Ratios

The trailing PE ratio is 55.34 and the forward PE ratio is 40.25. CORONA Remedies's PEG ratio is 1.62.

PE Ratio	55.34
Forward PE	40.25
PS Ratio	7.30
PB Ratio	13.72
P/TBV Ratio	21.17
P/FCF Ratio	185.14
P/OCF Ratio	44.65
PEG Ratio	1.62

Enterprise Valuation

The stock's EV/EBITDA ratio is 35.29, with an EV/FCF ratio of 187.32.

EV / Earnings	56.00
EV / Sales	7.39
EV / EBITDA	35.29
EV / EBIT	40.52
EV / FCF	187.32

Financial Position

The company has a current ratio of 0.96, with a Debt / Equity ratio of 0.22.

Current Ratio	0.96
Quick Ratio	0.53
Debt / Equity	0.22
Debt / EBITDA	0.56
Debt / FCF	2.98
Interest Coverage	36.67

Financial Efficiency

Return on equity (ROE) is 27.36% and return on invested capital (ROIC) is 25.62%.

Return on Equity (ROE)	27.36%
Return on Assets (ROA)	14.96%
Return on Invested Capital (ROIC)	25.62%
Return on Capital Employed (ROCE)	30.28%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	3.12M
Profits Per Employee	411,378
Employee Count	4,500
Asset Turnover	1.31
Inventory Turnover	2.05

Taxes

In the past 12 months, CORONA Remedies has paid 553.00 million in taxes.

Income Tax	553.00M
Effective Tax Rate	23.00%

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	1,643.67
200-Day Moving Average	n/a
Relative Strength Index (RSI)	49.84
Average Volume (20 Days)	46,187

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, CORONA Remedies had revenue of INR 14.03 billion and earned 1.85 billion in profits. Earnings per share was 30.27.

Revenue	14.03B
Gross Profit	11.42B
Operating Income	2.56B
Pretax Income	2.40B
Net Income	1.85B
EBITDA	2.93B
EBIT	2.56B
Earnings Per Share (EPS)	30.27

Balance Sheet

The company has 441.20 million in cash and 1.65 billion in debt, with a net cash position of -1.21 billion or -19.74 per share.

Cash & Cash Equivalents	441.20M
Total Debt	1.65B
Net Cash	-1.21B
Net Cash Per Share	-19.74
Equity (Book Value)	7.47B
Book Value Per Share	122.09
Working Capital	-128.60M

Cash Flow

In the last 12 months, operating cash flow was 2.29 billion and capital expenditures -1.74 billion, giving a free cash flow of 553.40 million.

Operating Cash Flow	2.29B
Capital Expenditures	-1.74B
Depreciation & Amortization	378.70M
Net Borrowing	773.80M
Free Cash Flow	553.40M
FCF Per Share	9.05

Margins

Gross margin is 81.40%, with operating and profit margins of 18.21% and 13.19%.

Gross Margin	81.40%
Operating Margin	18.21%
Pretax Margin	17.13%
Profit Margin	13.19%
EBITDA Margin	20.91%
EBIT Margin	18.21%
FCF Margin	3.94%

Dividends & Yields

This stock pays an annual dividend of 10.00, which amounts to a dividend yield of 0.59%.

Dividend Per Share	10.00
Dividend Yield	0.59%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	24.15%
Buyback Yield	0.01%
Shareholder Yield	0.59%
Earnings Yield	1.81%
FCF Yield	0.54%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	5